doi: 10.1097/00002826-198604000-00006.
Effect of supplemental carbidopa on bioavailability of L-dopa
- PMID:3085927
- DOI: 10.1097/00002826-198604000-00006
Item in Clipboard
Effect of supplemental carbidopa on bioavailability of L-dopa
J M Cedarbaum et al. Clin Neuropharmacol.1986.
Display options
Format
Display options
Format
Abstract
The effect of doubling carbidopa intake on single dose bioavailability of L-Dopa was examined in five parkinsonian patients. Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h. Increasing the within-dose ratio of carbidopa to L-Dopa, even in patients receiving "maximally effective" doses of carbidopa, further increases bioavailability of L-Dopa, presumably by inhibiting "first pass' metabolism in the gut.
Similar articles
- Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.Melamed E, Bitton V, Zelig O.Melamed E, et al.Neurology. 1986 Jan;36(1):100-3. doi: 10.1212/wnl.36.1.100.Neurology. 1986.PMID:3941762
- Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.Papavasiliou PS, McDowell FH, Wang YY, Rosal V, Miller ST.Papavasiliou PS, et al.Neurology. 1979 Feb;29(2):194-200. doi: 10.1212/wnl.29.2.194.Neurology. 1979.PMID:571063
- Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.Contin M, Riva R, Martinelli P, Procaccianti G, Baruzzi A.Contin M, et al.Clin Neuropharmacol. 1989 Feb;12(1):75-81. doi: 10.1097/00002826-198902000-00010.Clin Neuropharmacol. 1989.PMID:2713868
- Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).Stocchi F, Marconi S.Stocchi F, et al.Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924.Clin Neuropharmacol. 2010.PMID:20414107Review.
- Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Müller T.Müller T.Clin Neuropharmacol. 2013 May-Jun;36(3):84-91. doi: 10.1097/WNF.0b013e31828f3385.Clin Neuropharmacol. 2013.PMID:23673910Review.
Cited by
- Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.Brod LS, Aldred JL, Nutt JG.Brod LS, et al.Mov Disord. 2012 May;27(6):750-3. doi: 10.1002/mds.24998. Epub 2012 Apr 16.Mov Disord. 2012.PMID:22508376Free PMC article.Clinical Trial.
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.Katzenschlager R, et al.J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.J Neurol Neurosurg Psychiatry. 2004.PMID:15548480Free PMC article.Clinical Trial.
- Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.Schneider F, Erisson L, Beygi H, Bradbury M, Cohen-Barak O, Grachev ID, Guzy S, Loupe PS, Levi M, McDonald M, Savola JM, Papapetropoulos S, Tracewell WG, Velinova M, Spiegelstein O.Schneider F, et al.Br J Clin Pharmacol. 2018 Oct;84(10):2422-2432. doi: 10.1111/bcp.13702. Epub 2018 Aug 9.Br J Clin Pharmacol. 2018.PMID:29959802Free PMC article.Clinical Trial.
- Levodopa in Parkinson's Disease: Current Status and Future Developments.Tambasco N, Romoli M, Calabresi P.Tambasco N, et al.Curr Neuropharmacol. 2018;16(8):1239-1252. doi: 10.2174/1570159X15666170510143821.Curr Neuropharmacol. 2018.PMID:28494719Free PMC article.Review.
- Clinical pharmacokinetics of anti-parkinsonian drugs.Cedarbaum JM.Cedarbaum JM.Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.Clin Pharmacokinet. 1987.PMID:3311529Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical